NCT07410637 Impact of Thyroid Hormones on Human Glucose and Energy Metabolism
| NCT ID | NCT07410637 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Ulm |
| Condition | Graves Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-02-04 |
| Primary Completion | 2031-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-02-04 with a primary completion date of 2031-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial to clarify the impact of changes in thyroid hormone levels on glucose and lipid metabolism. Patients will be included in whom thyroid hormone levels are intentionally changed by treatment. In patients with Graves' disease, thyroid hormone levels will be lowered using medication, while in patients with thyroid cancer, thyroid hormone levels will be raised using medication. Oral glucose tolerance tests will be performed before treatment and at two time points after treatment begins to assess metabolic effects.
Eligibility Criteria
Inclusion Criteria: * patients with initial diagnosis of graves disease OR * patients with initial diagnosis of thyroid carcinoma Exclusion Criteria: * contraindications for oral glucose tolerance test * Diabetes mellitus * Fasting glucose level ≥ 200 mg/dL * Exogenous insulin administration with action at the time of the test * Current disease with activation of stress hormones * Post-aggressive metabolism * Acute infectious disease
Contact & Investigator
Martin Heni
PRINCIPAL INVESTIGATOR
University of Ulm
Frequently Asked Questions
Who can join the NCT07410637 clinical trial?
This trial is open to participants of all sexes, studying Graves Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07410637 currently recruiting?
Yes, NCT07410637 is actively recruiting participants. Contact the research team at martin.heni@uniklinik-ulm.de for enrollment information.
Where is the NCT07410637 trial being conducted?
This trial is being conducted at Ulm, Germany.
Who is sponsoring the NCT07410637 clinical trial?
NCT07410637 is sponsored by University of Ulm. The principal investigator is Martin Heni at University of Ulm. The trial plans to enroll 60 participants.